CTOs on the Move

Bioanalytical Systems

www.basinc.com

 
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.basinc.com
  • 2701 Kent Ave
    West Lafayette, IN USA 47906
  • Phone: 765.463.4527

Executives

Name Title Contact Details

Similar Companies

Tango2

Tango2 is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DocuMed Medical Transcriptions

DocuMed Medical Transcriptions is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hackenberg and Associates

Hackenberg and Associates is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CRI Worldwide

CRI Worldwide is a Clementon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.